Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
View in:
PubMed
subject areas
Adoptive Transfer
Animals
CD8-Positive T-Lymphocytes
Cell Line, Tumor
Cytotoxicity, Immunologic
Disease Models, Animal
Gene Expression
Genetic Engineering
Heterografts
Humans
I-kappa B Kinase
Interferon-gamma
Lymphocyte Count
Lymphocytes, Tumor-Infiltrating
Mice
Mice, Transgenic
Neoplasms
NF-kappa B
Signal Transduction
T-Lymphocytes
Tumor Burden
authors with profiles
Luciana Molinero
Maria-Luisa Alegre
Thomas F. Gajewski